Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: A meta-analysis of randomized trials

Atherosclerosis

Volumn 233, Issue 2, 2014, Pages 568-578

  Tang, Xiao Fang ^a   Fan, Jing Yao ^a   Meng, Jing ^b   Jin, Chen ^a   Yuan, Jin Qing ^a   Yang, Yue Jin ^a  

^a FUWAI HOSPITAL   (China)

^b BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Antiplatelet therapy; Coronary artery disease; Meta analysis; P2Y12 inhibitors

Indexed keywords

CANGRELOR; CLOPIDOGREL; ELINOGREL; PRASUGREL; TICAGRELOR; ADENOSINE; ADENOSINE PHOSPHATE; FIBRINOLYTIC AGENT; PIPERAZINE DERIVATIVE; PURINERGIC P2Y RECEPTOR ANTAGONIST; QUINAZOLINONE DERIVATIVE; SULFONAMIDE; THIOPHENE DERIVATIVE; TICLOPIDINE;

BLEEDING; BLOOD CLOT LYSIS; CARDIOVASCULAR RISK; CAUSE OF DEATH; COHORT ANALYSIS; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; HEART DISEASE; HEART INFARCTION; HUMAN; ISCHEMIA; META ANALYSIS; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTEMATIC REVIEW; ACUTE CORONARY SYNDROME; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COMPLICATION; CORONARY RESTENOSIS; FIBRINOLYTIC THERAPY; HEMORRHAGE; INTRAVENOUS DRUG ADMINISTRATION; MULTICENTER STUDY (TOPIC); MYOCARDIAL INFARCTION; ORAL DRUG ADMINISTRATION; STATISTICS AND NUMERICAL DATA; STENT; STROKE;

ACUTE CORONARY SYNDROME; ADENOSINE; ADENOSINE MONOPHOSPHATE; ADMINISTRATION, ORAL; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; INJECTIONS, INTRAVENOUS; MULTICENTER STUDIES AS TOPIC; MYOCARDIAL INFARCTION; PIPERAZINES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; QUINAZOLINONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STENTS; STROKE; SULFONAMIDES; THIOPHENES; THROMBOLYTIC THERAPY; TICLOPIDINE;

EID: 84896269765     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.01.017     Document Type: Review

References (44)

1. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation. NEngl J Med 2001, 345:494-502.
2. Steinhubl S.R., Berger P.B., Mann J.T., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAm Med Assoc 2002, 288:2411-2420.
3. Sabatine M.S., Cannon C.P., Gibson C.M., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with st-segment elevation. NEngl J Med 2005, 352:1179-1189.
4. Chen Z.M., Jiang L.X., Chen Y.P., et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005, 366:1607-1621.
5. Serebruany V.L., Steinhubl S.R., Berger P.B., Malinin A.I., Bhatt D.L., Topol E.J. Variability in platelet responsiveness to clopidogrel among 544 individuals. JAm Coll Cardiol 2005, 45:246-251.
6. Mehta S.R., Tanguay J.F., Eikelboom J.W., et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (current-oasis 7): a randomised factorial trial. Lancet 2010, 376:1233-1243.
7. Price M.J., Berger P.B., Teirstein P.S., et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the gravitas randomized trial. JAm Med Assoc 2011, 305:1097-1105.
8. Wallentin L., Varenhorst C., James S., et al. Prasugrel achieves greater and faster p2y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008, 29:21-30.
9. Gurbel P.A., Bliden K.P., Butler K., et al. Randomized double-blind assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the onset/offset study. Circulation 2009, 120:2577-2585.
10. Greenbaum A.B., Grines C.L., Bittl J.A., et al. Initial experience with an intravenous p2y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase ii, multicenter, randomized, placebo- and active-controlled trial. Am Heart J 2006, 151:689.e1-689.e10.
11. Berger J.S., Roe M.T., Gibson C.M., et al. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible p2y12 adp-receptor antagonist, before primary percutaneous intervention in patients with st-elevation myocardial infarction: the early rapid reversal of platelet thrombosis with intravenous elinogrel before pci to optimize reperfusion in acute myocardial infarction (erase mi) pilot trial. Am Heart J 2009, 158:998-1004. e1001.
12. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. NEngl J Med 2007, 357:2001-2015.
13. Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. NEngl J Med 2009, 361:1045-1057.
14. Bhatt D.L., Lincoff A.M., Gibson C.M., et al. Intravenous platelet blockade with cangrelor during pci. NEngl J Med 2009, 361:2330-2341.
15. Harrington R.A., Stone G.W., McNulty S., et al. Platelet inhibition with cangrelor in patients undergoing pci. NEngl J Med 2009, 361:2318-2329.
16. Bhatt D.L., Stone G.W., Mahaffey K.W., et al. Effect of platelet inhibition with cangrelor during pci on ischemic events. NEngl J Med 2013, 368:1303-1313.
17. Welsh R.C., Rao S.V., Zeymer U., et al. Arandomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral p2y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the innovate-pci trial. Circ Cardiovasc Interv 2012, 5:336-346.
18. Wiviott S.D., Antman E.M., Winters K.J., et al. Randomized comparison of prasugrel (cs-747, ly640315), a novel thienopyridine p2y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the joint utilization of medications to block platelets optimally (jumbo)-timi 26 trial. Circulation 2005, 111:3366-3373.
19. White H.D., Chew D.P., Dauerman H.L., et al. Reduced immediate ischemic events with cangrelor in pci: a pooled analysis of the champion trials using the universal definition of myocardial infarction. Am Heart J 2012, 163:182-190. e184.
20. Cutlip D.E., Windecker S., Mehran R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007, 115:2344-2351.
21. Cannon C.P., Husted S., Harrington R.A., et al. Safety, tolerability, and initial efficacy of azd6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-st-segment elevation acute coronary syndrome: primary results of the disperse-2 trial. JAm Coll Cardiol 2007, 50:1844-1851.
22. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
23. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
24. Trenk D., Stone G.W., Gawaz M., et al. Arandomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the trigger-pci (testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel) study. JAm Coll Cardiol 2012, 59:2159-2164.
25. Roe M.T., Armstrong P.W., Fox K.A., et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. NEngl J Med 2012, 367:1297-1309.
26. Montalescot G., Wiviott S.D., Braunwald E., et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for st-elevation myocardial infarction (triton-timi 38): double-blind, randomised controlled trial. Lancet 2009, 373:723-731.
27. Steg P.G., James S., Harrington R.A., et al. Ticagrelor versus clopidogrel in patients with st-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a platelet inhibition and patient outcomes (plato) trial subgroup analysis. Circulation 2010, 122:2131-2141.
28. Lindholm D., Varenhorst C., Cannon C., et al. Ticagrelor versus clopidogrel in patients with non-st-elevation acute coronary syndrome: results from the plato trial. JAm Coll Cardiol 2013, 61:E1.
29. Hamm C.W., Bassand J.P., Agewall S., et al. Esc guidelines for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation: the task force for the management of acute coronary syndromes (acs) in patients presenting without persistent st-segment elevation of the european society of cardiology (esc). Eur Heart J 2011, 32:2999-3054.
30. Levine G.N., Bates E.R., Blankenship J.C., et al. 2011 accf/aha/scai guideline for percutaneous coronary intervention. A report of the american college of cardiology foundation/american heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. JAm Coll Cardiol 2011, 58:e44-122.
31. O'Gara P.T., Kushner F.G., Ascheim D.D., et al. 2013 accf/aha guideline for the management of st-elevation myocardial infarction: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 2013, 127:e362-425.
32. Steg P.G., James S.K., Atar D., et al. Esc guidelines for the management of acute myocardial infarction in patients presenting with st-segment elevation. Eur Heart J 2012, 33:2569-2619.
33. Mehta S.R., Bassand J.P., Chrolavicius S., et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. NEngl J Med 2010, 363:930-942.
34. Aradi D., Komocsi A., Vorobcsuk A., Serebruany V.L. Impact of clopidogrel and potent p2y12-inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Thromb Haemost 2013, 109:93-101.
35. Bellemain-Appaix A., Brieger D., Beygui F., et al. New p2y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis. JAm Coll Cardiol 2010, 56:1542-1551.
36. Pocock S.J., Mehran R., Clayton T.C., et al. Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the acute catheterization and urgent intervention triage strategy trial. Circulation 2010, 121:43-51.
37. Chechi T., Vecchio S., Vittori G., et al. St-segment elevation myocardial infarction due to early and late stent thrombosis a new group of high-risk patients. JAm Coll Cardiol 2008, 51:2396-2402.
38. Testa L., Bhindi R., Van Gaal W.J., et al. What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel. QJM 2010, 103:367-377.
39. Heestermans A.A., van Werkum J.W., Taubert D., et al. Impaired bioavailability of clopidogrel in patients with a st-segment elevation myocardial infarction. Thromb Res 2008, 122:776-781.
40. Alexopoulos D., Xanthopoulou I., Gkizas V., et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with st-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012, 5:797-804.
41. Agrawal K., Bhatt D.L. Antiplatelet therapy: does prasugrel or ticagrelor suffice in patients with stemi?. Nat Rev Cardiol 2013, 10:121-122.
42. Bonello L., Pansieri M., Mancini J., et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. JAm Coll Cardiol 2011, 58:467-473.
43. Souckova L., Opatrilova R., Suk P., et al. Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (cpr). Eur J Clin Pharmacol 2013, 69:309-317.
44. Angiolillo D.J., Schneider D.J., Bhatt D.L., et al. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (champion) trials. JThromb Thrombolysis 2012, 34:44-55.